Explore original, structured summaries for research and education.
Research profile
DSIP(Delta Sleep-Inducing Peptide)
DSIP(Delta Sleep-Inducing Peptide) is indexed as a Nonapeptide research entry. Its current evidence category is (Delta Sleep-Inducing Peptide), and published discussion commonly places it within Cognitive, Sleep. This profile summarizes identifiers and literature signals; it does not provide treatment or dosing advice.
Identity
Molecular Data
- Molecular weight
- 848.81 Da
- Chain length
- 9 amino acids
- Type
- Nonapeptide
- Reported half-life
- ~15 minutes (in vitro)
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluLiterature map
Research indications
Sleep
- Deep Sleep Enhancementmost effective
- Sleep Efficiencymost effective
- Natural Sleep Architectureeffective
Mood
- Stress Response Modulationeffective
- Mood Stabilizationeffective
- Anxiety Reductioneffective
Pain & Recovery
- Pain Modulationmoderate
- Withdrawal Supportmoderate
- Athletic Recoverymoderate
Evidence-gated guidance
Dosing Protocols
No established human dosing protocol is recognized for this research entry. Animal, laboratory, community, or vendor regimens must not be converted into personal dosing instructions.
- Dose
- Not established on this profile
- Frequency
- Not established on this profile
- Cycle
- Not established on this profile
- Storage
- Follow the exact supplier or authorized product documentation; requirements vary by formulation
Combination risks
Interactions
Evidence status
No independently verified interaction table is available here for DSIP(Delta Sleep-Inducing Peptide). Interaction risk depends on identity, formulation, medicines, supplements, and health conditions.
Do not infer compatibility
Being listed beside another compound does not mean that combining them is safe or effective.
Evidence-informed overview
What to Expect
Evidence boundary
Research indications describe topics studied in the literature; they do not predict an individual outcome.
Clinical monitoring
Where an authorized medicinal use exists, expectations and monitoring should come from the current product label and treating clinician.
Risk overview
Side Effects & Safety
The safety profile of DSIP(Delta Sleep-Inducing Peptide) cannot be inferred from category or molecular identity alone. Research-only materials are not medicines and should not be used in humans.
Verification
Quality Checklist
- Confirm exact chemical identity, sequence, salt form, and concentration.
- Require a batch-specific certificate of analysis with named test methods and results.
- Check manufacturer, lot, expiry, tamper evidence, and documented chain of custody.
- For laboratory work requiring sterility, verify sterility and endotoxin testing separately from purity.
Clear answers
Frequently Asked Questions
Is DSIP(Delta Sleep-Inducing Peptide) approved for personal use?
This catalogue does not identify an authorized personal-use indication. Treat it as research information unless a current local regulator says otherwise.
Why is no dose listed?
A dose is shown only when it has been checked against a current authoritative prescribing label. Speculative or community regimens are intentionally excluded.
Do research indications prove effectiveness?
No. They organize literature topics and evidence signals; they are not treatment recommendations or guarantees.
Source trail
References
- Effects of Delta Sleep-Inducing Peptide on Sleep of Chronic Insomniac Patients: A Double-Blind StudySchneider-Helmert D · Neuropsychobiology · 1992
- Therapeutic Effects of Delta-Sleep-Inducing Peptide (DSIP) in Patients with Chronic, Pronounced Pain Episodes: A Clinical Pilot StudySchoenenberger GA, Schneider-Helmert D · European Neurology · 1984
- DSIP in the Treatment of Withdrawal Syndromes from Alcohol and OpiatesDick P, Costa C, Fayolle K, et al. · European Neurology · 1984
- Acute and Delayed Effects of DSIP (Delta Sleep-Inducing Peptide) on Human Sleep BehaviorSchneider-Helmert D, Schoenenberger GA · International Journal of Peptide and Protein Research · 1983
- Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats After Focal StrokeTukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. · Pharmaceutics · 2021
- Successful Treatment of Withdrawal Symptoms with Delta Sleep-Inducing PeptideLarbig W, Gerber WD, Kluck M, Schoenenberger GA · Neuropsychobiology · 1984
